China has approved the “conditional” use of the Pfizer drug against it coronaviruswhich is marketed under the brand name Paxlovid, as announced by the country’s national drug service.
The decision comes as Beijing is hosting the Winter Olympics and the country is facing some sporadic outbreaks of the virus. However, so far, Chinese authorities have not approved any foreign vaccine against Covid-19.
Paxlovid was licensed in late December in the United States and in about 40 countries since then. THE Pfizer has sold $ 72 million worth of the drug in 2021 and hopes to produce 120 million doses throughout 2022.
The Chinese National Medical Products Authority approved the use of this medicinal product “under certain conditions” and, like other countries, only for patients who are at risk of developing a severe form of Covid-19, she says on her website.
Pfizer will continue to study its drug and submit the results to the Chinese regulator, it said in a statement.
THE China The outbreak of the epidemic is followed by a zero-tolerance strategy in Covid-19, which consists of making every effort to limit the occurrence of new cases, which generally amount to only a few dozen per day.
For example, the country’s Ministry of Health today announced only 40 new domestic infections across the country.
Although these numbers are very low compared to those recorded daily in other countries of the world, they push the authorities to double the vigilance again when Beijing is hosting the Winter Olympics until February 20.
Source: News Beast
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
